Recurrent VTE rates during follow-up in patients with different APA findings
| Group . | N of patients . | N of VTE events . | Person-years . | Event rate per 100 person-years (95% CI) . |
|---|---|---|---|---|
| All patients | 290* | 34 | 627 | 5.4 (3.8-7.6) |
| No APA | 215 | 21 | 471 | 4.5 (2.8-6.8) |
| Any APA | 75 | 13 | 158 | 8.2 (4.4-14.1) |
| APA once† | 49 | 7 | 110 | 6.4 (2.6-13.1) |
| APA twice‡ | 26 | 6 | 46 | 13.0 (4.8-28.4) |
| ACA only§ | 11 | 1 | 28 | 3.6 (0.1-19.9) |
| IgG only‖ | 6 | 1 | 13 | 7.7 (0.2-42.9) |
| IgM only¶ | 5 | 0 | 14 | 0.0 (0.0-26.3) |
| Anti-β2GP1 only§ | 1 | 0 | 2 | 0.0 (0.0-184.4) |
| LA only§ | 52 | 8 | 108 | 7.4 (3.2-14.6) |
| 1 APA type# | 64 | 9 | 137 | 6.6 (3.0-12.5) |
| 2 APA types# | 9 | 4 | 12 | 33.1 (9.1-85.3) |
| 3 APA types# | 2 | 0 | 7 | 0.0 (0.0-52.7) |
| Group . | N of patients . | N of VTE events . | Person-years . | Event rate per 100 person-years (95% CI) . |
|---|---|---|---|---|
| All patients | 290* | 34 | 627 | 5.4 (3.8-7.6) |
| No APA | 215 | 21 | 471 | 4.5 (2.8-6.8) |
| Any APA | 75 | 13 | 158 | 8.2 (4.4-14.1) |
| APA once† | 49 | 7 | 110 | 6.4 (2.6-13.1) |
| APA twice‡ | 26 | 6 | 46 | 13.0 (4.8-28.4) |
| ACA only§ | 11 | 1 | 28 | 3.6 (0.1-19.9) |
| IgG only‖ | 6 | 1 | 13 | 7.7 (0.2-42.9) |
| IgM only¶ | 5 | 0 | 14 | 0.0 (0.0-26.3) |
| Anti-β2GP1 only§ | 1 | 0 | 2 | 0.0 (0.0-184.4) |
| LA only§ | 52 | 8 | 108 | 7.4 (3.2-14.6) |
| 1 APA type# | 64 | 9 | 137 | 6.6 (3.0-12.5) |
| 2 APA types# | 9 | 4 | 12 | 33.1 (9.1-85.3) |
| 3 APA types# | 2 | 0 | 7 | 0.0 (0.0-52.7) |
Does not include the 12 patients who had a positive qualitative D-dimer at enrollment and therefore did not stop anticoagulants.
Patients may have tested positive for ≥1 types of APAs, but no type of APA was present on 2 occasions. Includes patients who were tested for any APA once (n = 25), twice (n = 74), or 3 times (n = 191); the same APA test was not performed more than twice.
Only includes patients who had the same type of APA on 2 occasions (consistent with the Sapporo-Sydney criteria for diagnosis of antiphospholipid syndrome).
Test may have been positive on 1 or 2 occasions.
Highest anticardiolipin IgG antibody level in each patient: 23, 31, 28, 24, 24, and 24 units (recurrent VTE).
Highest anticardiolipin IgM antibody level in each patient: 27, 35, 32, 54, and 48 units.
Tests may have been positive on the same or different occasions. Event rate for patients with either 2 or 3 APA types was 21.1 (95% CI, 5.7-53.9) per 100 person-years.